Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 12, 2007, Pages 4308-4314

  Garre B ^a   Shebany, K ^a   Gryspeerdt, A ^a   Baert, K ^a   Van Der Meulen, K ^a   Nauwynck, H ^a   Deprez, P ^a   De Backer, P ^a   Croubels, S ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; PRODRUG; VALACICLOVIR;

ANIMAL EXPERIMENT; ARTICLE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; EQUINE HERPES VIRUS; FEMALE; FLUORESCENCE; HERPES SIMPLEX VIRUS 1; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; STOMACH INTUBATION; TANDEM MASS SPECTROMETRY;

ACYCLOVIR; ADMINISTRATION, ORAL; ALGORITHMS; ANIMALS; ANTIVIRAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HORSES; INFUSIONS, INTRAVENOUS; METABOLIC CLEARANCE RATE; PRODRUGS; TANDEM MASS SPECTROMETRY; VALINE;

EID: 36749080375     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00116-07     Document Type: Article

References (31)

1. Allen, G. P., and J. T. Bryans. 1986. Molecular epizootiology, pathogenesis and prophylaxis of equine herpesvirus-1 infections. Prog. Vet. Microbiol. Immunol. 2:78-144.
2. Anonymous. 1993. Antiviral agents, 13th ed., p. 536-563. In J. E. F. Reynolds (ed.), Martindale, the Extra Pharmacopoeia. The Pharmaceutical Press, London, United Kingdom.
3. Anonymous. 2002. Commission Decision (2002/657/EC) of 17 August 2002 implementing Council Directive 96/23/EC concerning the performance of analytical methods and the interpretation of results. Official European Communication No. L221, p. 8. European Commission, Brussels, Belgium.
4. Barger, A., C. Fuhst, and B. Wiedemann. 2003. Pharmacological indices in antibiotic therapy. J. Antimicrob. Chemother. 52:893-898.
5. Bentz, B. G., L. K. Maxwell, R. S. Erkert, C. M. Royer, M. S. Davis, C. G. MacAllister, and C. R. Clarke. 2006. Pharmacokinetics of acyclovir after single intravenous and oral administration to adult horses. J. Vet. Intern. Med. 20:589-594.
6. Bryans, J. T., and G. P. Allen. 1989. Herpesviral diseases of the horse, p. 176-229. In G. Wittman (ed.), Herpesviral diseases of cattle, horses and pigs. Kluwer, Boston, MA.
7. de Miranda, P., R. J. Whitley, M. R. Blum, R. E. Keeney, N. Barton, D. M. Cocchetto, S. Good, G. P. Hemstreet, L. E. Kirk, D. A. Page, and G. B. Elion. 1979. Acyclovir kinetics after intravenous infusion. Clin. Pharmacol. Ther. 26:718-728.
8. Dorsky, D. I., and C. S. Crumpacker. 1987. Drugs five years later: acyclovir. Ann. Intern. Med. 107:859-874.
9. Fletcher, C., and B. Bean. 1985. Evaluation of oral acyclovir therapy. Drug. Intell. Clin. Pharm. 19:518-524.
10. Friday, P. A., W. K. Scarratt, F. Elvinger, P. J. Timoney, and A. Bonda. 2000. Ataxia and paresis with equine herpesvirus type 1 infection in a herd of a riding school horses. J. Vet. Intern. Med. 14:197-201.
11. Gabrielsson, J. L., and D. L. Weiner. 1999. Methodology for pharmacokinetic/pharmacodynamic data analysis. Pharm. Sci. Technol. Today 2:244-252.
12. Garré, B., K. Van der Meulen, J. Nugent, J. Neyts, S. Croubels, P. De Backer, and H. Nauwynck. 2007. In vitro susceptibility of 6 isolates of equine herpes virus 1 to acyclovir, ganciclovir, cidofovir, adefovir, PMEDAP and foscarnet. Vet. Microbiol. 16:43-51.
13. Gibaldi, M., and D. Perrier (ed.). 1982. Pharmacokinetics, 2nd ed. rev. and expanded. Marcel Dekker Inc., New York, NY.
14. Henninger, R. 2003. Epidemic neurological disease due to equine herpesvirus 1: the University of Findlay English Equestrian Center, p. 621-624. Presented at the International Veterinary Emergency and Critical Care Symposium 9th Annual Meeting, New Orleans, LA.
15. Krasny, H. C., P. de Miranda, M. R. Blum, and G. B. Elion. 1981. Pharmacokinetics and bioavailability of acyclovir in the dog. J. Pharmacol. Exp. Ther. 216:218-288.
16. MacDougall, C., and B. J. Guglielmo. 2004. Pharmacokinetics of valaciclovir. J. Antimicrob. Chemother. 53:899-901.
17. McMartan, C. G., M. M. Russell, J. L. N. Wood, and J. A. Mumford. 1995. Clinical, serological and virological characteristics of an outbreak of paresis and neonatal foal disease due to equine herpesvirus-1 on a stud farm. Vet. Rec. 136:7-12.
18. Meadows, K. C., and J. B. Dressman. 1990. Mechanism of acyclovir uptake in rat jejunum. Pharm. Res. 7:299-303.
19. Murray, M. J., F. del Piero, S. C. Jeffrey, M. S. Davis, M. O. Furr, E. J. Dubovi, and J. A. Mayo. 1998. Neonatal equine herpesvirus type 1 infection on a thoroughbred breeding farm. J. Vet. Intern. Med. 12:36-41.
20. Ormrod, D., and K. Goa. 2000. Valaciclovir. A review of its use in the management of herpes zoster. Drugs 59:1317-1340.
21. Ostlund, E. N. 1993. The equine herpesvirus. Vet. Clin. N. Am. Equine Pract. 9:283-294.
22. Perry, C. M., and D. Faulds. 1996. Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs 52:754-772.
23. Slater, J. D., D. P. Jun, D. W. Horohov, D. F. Antczak, L. Babiuk, C. Breathnach, Y. W. Chang, N. Davis-Poynter, N. Edington, S. Ellis, C. Foote, L. Goehring, C. W. Kohn, J. Kydd, T. Matsumura, J. Minke, P. Morley, J. Mumford, T. Neubauer, D. O'Callaghan, K. Osterieder, S. Reed, K. Smith, H. Townsend, K. van der Meulen, M. Whalley, and W. D. Wilson. 2006. Report of the equine herpesvirus-1 Havermeyer Workshop, San Gimignano, Tuscany, June 2004. Vet. Immunol. Immunopathol. 15:3-13.
24. Stierstorfer, B., W. Eichhorn, W. Schmahl, C. Brandmuller, O. R. Kaaden, and A. Neubauer. 2002. Equine herpesvirus type 1 (EHV-1) myeloencephalopathy: a case report. J. Vet. Med. B Infect. Dis. Vet. Public Health 49:37-41.
25. Tanna, S., C. Wood, and M. J. Lawrence. 1992. Competition studies to elucidate the mechanisms of acyclovir uptake in the small intestine. J. Pharm. Pharmacol. 44(Suppl. 1):1047.
26. Tod, M., F. Lokiec, R. Bidault, F. De Bony, O. Petitjean, Y. Aujard, and the Acyclovir Pediatric French Group. 2001. Pharmacokinetics of oral acyclovir in neonate and infants: a population analysis. Antimicrob. Agents Chemother. 45:150-157.
27. van der Meulen, K. M., G. Vercauteren, H. J. Nauwynck, and M. B. Pensaert. 2003. A local epidemic of equine herpesvirus 1-induced neurological disorders in Belgium. Flem. Vet. J. 72:366-372.
28. van Maanen, C., M. M. Sloet van Oldruiterborgh-Oosterbaan, E. A. Damen, and A. G. Derksen. 2001. Neurological disease associated with EHV-1 infection in a riding school: clinical and virological characteristics. Equine Vet. J. 33:191-196.
29. Wilkins, P. A. 2004. Acyclovir in the treatment of EHV-1 myeloencephalopathy, p. 170-172. Presented at the American College of Veterinary Internal Medicine 22nd Annual Meeting, Minneapolis, MN.
30. Wilkins, P. A., M. Papich, and R. W. Sweeney. 2005. Pharmacokinetics of acyclovir in adult horses. J. Vet. Emergency Crit. Care 15:174-178.
31. Yamaoka, K., T. Nakagawa, and T. Uno. 1978. Application of Akaike's information criteria (AIC) in the evaluation of linear pharmacokinetics. J. Pharmacokinet. Biopharm. 6:165-175.